DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Robin Foster HealthDay - 1 “ ASPR - 1 haven't - 1 Biden - 1 Joe Biden - 1 – - 1 Ridgeback Biotherapeutics - 1 Molnupiravir - 1
Top related locs:
U.S – COVID United States
Top related orgs:
Administration - 3 Strategic Preparedness - 3 U.S . Department of Health - 2 Human Services - 2 U.S . Food - 2 Drug Administration - 2 CDC - 2 CNN - 1

Search resuls for: "Strategic Preparedness"


6 mentions found


☆ Free COVID Test Orders to End on March 8
  + stars: | 2024-03-06 | by ( March | At A.M. | ) www.usnews.com   time to read: +2 min
By Robin Foster HealthDay ReporterHealthDayWEDNESDAY, March 6, 2024 (HealthDay News) -- Americans will not be able to order free at-home COVID tests after Friday, U.S. health officials announced Tuesday. Households across the country have been able to order four free rapid antigen tests through COVID.gov. The federal government previously suspended the free rapid test program last May after the public health emergency of the pandemic was officially ended. The CDC recommends that people test if they have any COVID symptoms including a sore throat, a runny nose, loss of smell or taste or a fever. More informationVisit the CDC for more on COVID testing.
Persons: Robin Foster HealthDay, “ ASPR, haven't Organizations: Administration, Strategic Preparedness, U.S . Department of Health, Human Services, CNN, U.S . Food, Drug Administration, CDC Locations: U.S
☆ Biden Administration Relaxes COVID-19 Guidance, Resources as Winter Wave Shifts Into Rear View
  + stars: | 2024-03-05 | by ( Cecelia Smith-Schoenwalder | March | At P.M. | ) www.usnews.com   time to read: +2 min
The Biden administration is relaxing its COVID-19 protocols and resources as the winter wave of the coronavirus appears past its peak and fading. Political Cartoons on Women’s Issues View All 53 ImagesThe developments altogether highlight the dwindling bandwidth the Biden administration lends to COVID-19 as the U.S. enters its fifth year dealing with the coronavirus. Several COVID-19 factors are decreasing in the U.S. – a likely indicator that the winter wave of coronavirus is behind us. Data shows the latest increase in COVID-19 activity was significantly less dangerous than the COVID-19 surges the U.S. saw early in the pandemic. “Despite the high levels of wastewater viral activity, COVID-19 is causing severe disease less frequently than earlier in the pandemic,” the CDC said in a recent update.
Persons: Biden, Joe Biden, – Organizations: Administration, Strategic Preparedness, ., Centers for Disease Control, CDC Locations: U.S, –, COVID
☆ US plans shift of Merck COVID treatment to commercial market
  + stars: | 2023-10-04 | by ( Michael Erman | ) www.reuters.com   time to read: +3 min
A COVID-19 treatment pill, called molnupiravir developed by Merck & Co and Ridgeback Biotherapeutics LP is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS/File photo Acquire Licensing RightsOct 4 (Reuters) - The U.S. government will stop distributing free doses of Merck & Co's (MRK.N) COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead. Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available but was soon eclipsed by Pfizer's (PFE.N) rival treatment Paxlovid, which had more impressive data. Merck said the study was limited and that it is confident in the clinical profile of the drug. Merck said it would have a patient assistance program for people who cannot afford the drug.
Persons: Ridgeback Biotherapeutics, Molnupiravir, Merck, Michael Erman, Bill Berkrot Organizations: Merck & Co, Merck & Co Inc, Reuters, Merck, Co Inc, REUTERS, U.S, Co's, Administration, Strategic Preparedness, U.S . Department of Health, Human Services, U.S . Food, Drug Administration, Pfizer's, Thomson Locations: U.S, United States
☆ As Ebola outbreak grows in Uganda, US ramps up preparedness plans
  + stars: | 2022-11-16 | by ( Jacqueline Howard | ) edition.cnn.com   time to read: +8 min
“All primary and secondary schools in Uganda are directed to close by November 25th, 2022 for third term holidays as a measure to contain Ebola Virus Disease (EVD) in the country,” Museveni said in a statement. Major US cities get Ebola plans in placeThe CDC estimates that 20% of travelers from Uganda will arrive without a cell phone or US-based phone number. “CDPH continues to work with our hospitals to screen patients for travel history and be alert for symptoms of Ebola virus disease or, more likely, malaria or circulating respiratory viruses. ‘We need to be prepared’The Ebola virus is transmissible – but not as transmissible as some other infectious diseases, like Covid-19. “If we do see any cases in the United States, the hope is that they will be identified quickly before there is further spread,” Barouch said.
☆ Omicron subvariants pose a new threat to people with immune deficiencies
  + stars: | 2022-10-23 | by ( Benjamin Ryan | ) www.nbcnews.com   time to read: +7 min
Troubling recent reports reveal the emergence of new omicron subvariants that not only evade AstraZeneca’s Evusheld, the antibody drug authorized to prevent Covid infection, but also the sole antibody drug that has retained effectiveness as treatment for Covid, Eli Lilly’s bebtelovimab. Doctors have cautioned that should Laura get Covid, this could aggravate her autoimmune disease and lead to catastrophic kidney damage. Evusheld is a long-acting antibody injection given every six months that studies have suggested provides a robust buffer to the immunosuppressed. For now, immunocompromised people are anxiously watching the pandemic forecast to see if the subvariants that research indicates evade monoclonal antibodies will become predominant. “If fewer people are prescribed Evusheld,” she said, “there’s less incentive for drug companies to start developing newer therapeutics.
☆ Why U.S. purchase of radiation sickness drug Nplate is no cause for alarm
  + stars: | 2022-10-07 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com   time to read: +3 min
Amid concerns about Russian President Vladimir Putin’s recent nuclear threats came a bit of startling news: The U.S. Department of Health and Human Services said Tuesday that it spent $290 million on a drug to treat radiation sickness. Nplate, manufactured by U.S. drugmaker Amgen, was approved by the Food and Drug Administration in 2021 to treat injuries caused by acute radiation syndrome, also known as radiation sickness. Amgen will maintain the supply of the drug, an approach the HHS says lowers costs for taxpayers and allows the drug to be used in the commercial market before it expires. Chris Meekins, former deputy assistant secretary for preparedness and response at HHS, said that he sees no cause for alarm over the purchase. Greg Burel, the former director of the Strategic National Stockpile, agreed, saying that he doesn't think the HHS' purchase of the drug is related to the Russian invasion of Ukraine in February.
0 next >>
Total: 6